Top

Wits RHI

Wits RHI begins MATRIX-003 Phase 1 (Placebo) Trial: Pioneering Intravaginal Ring Designs for HIV Prevention and Contraception

We’re excited to announce the activation of the OCIS Placebo Ring Study – MATRIX-003 at the Wits RHI site. This pivotal clinical trial marks a significant advancement in evaluating the acceptability and safety of two new intravaginal ring (IVR) designs, representing a promising step forward in women’s sexual and reproductive health. The MATRIX-003 study will explore the usability, safety, and acceptability of two placebo IVR designs through a randomized, partially blinded crossover trial. The trial is structured with two study arms and aims to provide insights into how well adolescent girls, young women (AGYW), and potentially other populations adapt to and accept these innovative IVR options. MATRIX-003’s findings will support the development of a long-acting, dual-purpose IVR capable of preventing both HIV and unplanned pregnancies.

Study Goals
This trial will examine several key outcomes:

  1. Primary Goal: Evaluate participants’ acceptability of the two IVR designs.
  2. Secondary Goal: Assess safety outcomes, including the rate of urogenital adverse events.
  3. Exploratory Goal: Gain insights into participant and partner experiences, attitudes toward IVR use, and potential impacts on the vaginal microbiome.

We look forward to sharing updates as MATRIX-003 progresses, and we are committed to bringing new, empowering solutions to women’s health in South Africa and worldwide.